POLR2C: A Potential Drug Target and Biomarker (G5432)

Target Name: POLR2C

NCBI ID: G5432

POLR2C

POLR2C: A Potential Drug Target and Biomarker

POLR2C, or poly(ADP-ribose) polymerase 2C, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. POLR2C plays a crucial role in the regulation of DNA replication, which is a critical process for the development and maintenance of cellular organisms. The disruption of DNA replication has been implicated in the development and progression of many diseases, making POLR2C a promising target for therapeutic intervention.

Diseases and their link to POLR2C

The identification of POLR2C as a potential drug target and biomarker has been based on its involvement in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

POLR2C and cancer

POLR2C has been shown to be involved in the regulation of DNA replication in various cancer types. For example, studies have shown that the expression of POLR2C is highly correlated with the development and progression of colorectal cancer. Additionally, therapeutic intervention with compounds that target POLR2C has been shown to inhibit the growth of cancer cells in both in vitro and in vivo models.

POLR2C and neurodegenerative diseases

POLR2C is also involved in the regulation of DNA replication in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. The disruption of DNA replication has been implicated in the development and progression of these diseases, and therapeutic intervention with compounds that target POLR2C has been shown to improve cognitive function in animal models of these diseases.

POLR2C and autoimmune disorders

POLR2C has also been implicated in the regulation of DNA replication in autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. The disruption of DNA replication has been implicated in the development and progression of these diseases, and therapeutic intervention with compounds that target POLR2C has been shown to reduce inflammation and improve disease-related symptoms in animal models of these disorders.

Phenomenology and Potential Therapeutic Interventions

The regulation of DNA replication by POLR2C is a critical process for the development and maintenance of cellular organisms. The disruption of DNA replication has been implicated in the development and progression of many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, targeting POLR2C with therapeutic compounds has the potential to improve outcomes in these diseases.

POLR2C has been shown to play a crucial role in the regulation of DNA replication in various diseases. The disruption of DNA replication has been implicated in the development and progression of many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, targeting POLR2C with therapeutic compounds has the potential to improve outcomes in these diseases. Further studies are needed to fully understand the role of POLR2C in disease and to develop effective therapeutic interventions.

Protein Name: RNA Polymerase II Subunit C

Functions: DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphosphates as substrates. Component of RNA polymerase II which synthesizes mRNA precursors and many functional non-coding RNAs. Pol II is the central component of the basal RNA polymerase II transcription machinery. It is composed of mobile elements that move relative to each other. RPB3 is part of the core element with the central large cleft and the clamp element that moves to open and close the cleft (By similarity)

The "POLR2C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about POLR2C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets